Document is current
Any future updates will be listed below
-
Authors
Sept, Corriene E.
Tak, Y. Esther
Goel, Viraat https://orcid.org/0000-0002-5532-5756
Bhakta, Mital S.
Cerda-Smith, Christian G. https://orcid.org/0000-0001-8123-5300
Hutchinson, Haley M. https://orcid.org/0000-0002-8181-6022
Blanchette, Marco
Eyler, Christine E.
Johnstone, Sarah E.
Joung, J. Keith
Hansen, Anders S. https://orcid.org/0000-0001-7540-7858
Aryee, Martin J. https://orcid.org/0000-0002-6848-1344
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (RM1HG009490, R35GM118158, T32GM135117)
Novo Nordisk Fonden (NNF21SA0072102)
- License Information
-
More Information
Article History
Received: 27 October 2023
Accepted: 3 March 2025
First Online: 15 May 2025
Competing interests
: Dovetail Genomics/Cantata Bio provided reagents and sample processing for HiChIP experiments. M.B. and M.S.B were employees at Dovetail Genomics during the course of this research. M.J.A has financial and consulting interests unrelated to this work in SeQure Dx and Chroma Medicine. M.J.A’s interests are reviewed and managed by Dana Farber Cancer Institute. J.K.J. is a co-founder of and has a financial interest in SeQure, Dx, Inc., a company developing technologies for gene editing target profiling. JKJ also has, or had during the course of this research, financial interests in several companies developing gene editing technology: Beam Therapeutics, Blink Therapeutics, Chroma Medicine, Editas Medicine, EpiLogic Therapeutics, Excelsior Genomics, Hera Biolabs, Monitor Biotechnologies, Nvelop Therapeutics (f/k/a ETx, Inc.), Pairwise Plants, Poseida Therapeutics, and Verve Therapeutics. J.K.J.’s interests were reviewed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict of interest policies. M.J.A., Y.E.T., and J.K.J. are currently employees of Arena Bioworks. The remaining authors declare no competing interests.
